Sarepta Therapeutics Inc

Sarepta Therapeutics Inc

SRPT

Market Cap$1.97B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Sarepta Therapeutics IncSarepta Therapeutics Inc-7.9--22%0.91.3
$68.75

Target Price by Analysts

264.3% upsideSarepta Therapeutics Target Price DetailsTarget Price
$153.22

Current Fair Value

712% upside

Undervalued by 712% based on the discounted cash flow analysis.

Share Statistics

Market cap$1.97 Billion
Enterprise Value$3.20 Billion
Dividend Yield$0 (0%)
Earnings per Share$2.34
Beta0.6
Outstanding Shares97,362,000

Return

Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio-7.87
PEG0.59
Price to Sales0.86
Price to Book Ratio1.72
Enterprise Value to Revenue1.43
Enterprise Value to EBIT-16.35
Enterprise Value to Net Income-13
Total Debt to Enterprise0.46
Debt to Equity1.29

Revenue Sources

No data

Insider Trades

ESG Score

No data

About Sarepta Therapeutics Inc

CEO: Douglas Ingram

Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the...